Comparative Study of SIRT1 Expression in Hepatitis B Virus, Hepatitis C Virus, and Hepatocellular Carcinoma Patients

Document Type : Original Article

Authors

1 Department of Internal medicine, Faculty of Medicine, Beni-Suef University, Egypt

2 Department of Biochemistry, Faculty of Medicine, Cairo University, Egypt

3 Department of Internal medicine, One-day surgery Hospital, Minia, Egypt

Abstract

Background and Aim: The most common form of primary liver cancer in adults is hepatocellular carcinoma (HCC), and it is the most common cause of death in people with cirrhosis. The mammalian Sir2 family or sirtuins is formed of a cluster of highly conserved proteins triggering nicotinamide adenine dinucleotide (NAD)-dependent histone deacetylase activity which target histone and non-histone substrates including enzymes, transcription regulators, tumor suppressors, cell signaling proteins and DNA repair proteins. Seven human sirtuins have been identified and named SIRT1-7.  SIRT1 has been regarded as a tumor promoter due to its increased expression in some types of cancers and its role in the inactivation of proteins involved in tumor suppression and DNA damage repair.We aimed to estimate the level of SIRT-1 in the blood of HBV, HCV, and HCC patients, to investigate the possible role of SIRT-1 in the pathogenesis of HCC and to determine the role of SIRT-1 as a tumor marker or pomoter compared to other markers like α-feto protein. Subjects and Methods: This study was performed in Internal Medicine department Beni-Suef Hospital. Our study included 160 individuals; divided into four groups; group A (healthy control), group B (HBV patients), group C (HCV patients) and group D (HCC patients). The serum level of SIRT-1 was assessed and compared in all groups and correlate its level as a tumor marker with the other marker α-fetoprotein. Results: There was significant increase in SIRT-1 levels in HBV, HCV and HCC group as compared to control (p value <0.001). There was significant increase in SIRT-1 in HCV and HCC groups as compared to HBV group (p value <0.001). There was significant increase in SIRT-1 levels in HCC group as compared to HCV group (p value <0.001). There was positive correlation between α - feto protein and SIRT-1in HCC group only but no correlation in others groups. Conclusion: Our study demonstrated that SIRT-1 is overexpressed in HCC patients compared to chronic noncancerous viral liver parenchyma diseases, so it may be included in pathogenesis of HCC. SIRT-1 may have matchable specificity and sensitivity as AFP in HCC patients.

Keywords

Main Subjects

References

  1. Uranbileg, B., Kurano, M., Sato, M., Ikeda, H., Ishizawa, T., Hasegawa, K., Kokudo, N., & Yatomi, Y. (2020):  Possible involvement of PS-PLA1 and lysophosphatidylserine receptor (LPS1) in hepatocellular carcinoma. Scientific reports, 10(1), 2659.        
  2. Becatti, M., Fiorillo, C., Barygina, V., Cecchi, C., Lotti, T., Prignano, F., ... & Taddei, N. (2014):  SIRT 1 regulates MAPK pathways in vitiligo skin: insight into the molecular pathways of cell survival. Journal of cellular and molecular medicine, 18(3), 514-529.
  3. Krueger, J. G., Suárez-Fariñas, M., Cueto, I., Khacherian, A., Matheson, R., Parish, L. C., ... & Vlasuk, G. P. (2015): A randomized, placebo-controlled study of SRT2104, a SIRT1 activator, in patients with moderate to severe psoriasis. PloS one, 10(11), e0142081.
  4. Su, W. L., Chuang, S. C., Wang, Y. C., Chen, L. A., Huang, J. W., Chang, W. T., ... & Kuo, K. K. (2020):  Expression of FOXM1 and Aurora-A predicts prognosis and sorafenib efficacy in patients with hepatocellular carcinoma. Cancer Biomarkers, (Preprint), 1-10.
  5. Mohamed, S. Y., Gaballah, B. A., Elsadek, H. M., Emara, M. H., & Hamed, E. F. (2019): Resolved HBV behavior during the treatment of chronic HCV infection with direct-acting antivirals. Gastroenterology and Hepatology from Bed to Bench, 12(4), 301.
  6. Kuo, Y. H., Kee, K. M., Hsu, N. T., Wang, J. H., Hsiao, C. C., Chen, Y., & Lu, S. N. (2019):  Using AST-platelet ratio index and fibrosis 4 index for detecting chronic hepatitis C in a large-scale community screening. PloS one, 14(10), e0222196.
  7. O'Hara, G., Mokaya, J., Hau, J. P., Downs, L. O., McNaughton, A. L., Karabarinde, A., ... & Newton, R. (2020): Liver function tests and fibrosis scores in a rural population in Africa: a cross-sectional study to estimate the burden of disease and associated risk factors. BMJ open, 10(3), e032890.
  8. Eldeeb, M. K., Magour, G. M., Bedair, R. N., Shamseya, M. M., & Hammouda, M. A. (2020):  Study of Dickkopf-1 (DKK-1) in patients with chronic viral hepatitis C-related liver cirrhosis with and without hepatocellular carcinoma. Clinical and Experimental Hepatology, 6(2), 85.
  9. Li, L., Mo, F., Hui, E. P., Chan, S. L., Koh, J., Tang, N. L., ... & Yeo, W. (2019):  The association of liver function and quality of life of patients with liver cancer. BMC gastroenterology, 19(1), 66.
  10. Huang, J., Zheng, Y., Xiao, X., Liu, C., Lin, J., Zheng, S., ... & Ou, Q. (2020):  A Circulating Long Noncoding RNA Panel Serves as a Diagnostic Marker for Hepatocellular Carcinoma. Disease Markers, 2020.
  11. Goyal, L., Zheng, H., Abrams, T. A., Miksad, R., Bullock, A. J., Allen, J. N., ... & Knowles, M. (2019):  A phase II and biomarker study of sorafenib combined with modified FOLFOX in patients with advanced hepatocellular carcinoma. Clinical Cancer Research, 25(1), 80-89.
  12. Chen, Z., He, M., Chen, J., Li, C., & Zhang, Q. (2020):  Long non coding RNA SNHG7 inhibits NLRP3 dependent pyroptosis by targeting the miR 34a/SIRT1 axis in liver cancer. Oncology letters, 20(1), 893-901.
  13. Li, Y., Xu, S., Li, J., Zheng, L., Feng, M., Wang, X., ... & You, N. (2016): SIRT1 facilitates hepatocellular carcinoma metastasis by promoting PGC-1α-mediated mitochondrial biogenesis. Oncotarget, 7(20), 29255.
  14. Wang, Y., Cui, R., Zhang, X., Qiao, Y., Liu, X., Chang, Y., ... & Wang, J. (2016): SIRT1 increases YAP-and MKK3-dependent p38 phosphorylation in mouse liver and human hepatocellular carcinoma. Oncotarget, 7(10), 11284.
  15. Zhou, J., Zhou, W., Kong, F., Xiao, X., Kuang, H., & Zhu, Y. (2017): MicroRNA-34a overexpression inhibits cell migration and invasion via regulating SIRT1 in hepatocellular carcinoma. Oncology letters, 14(6), 6950–6954.
  16. Zhou, B., Yang, Y., & Li, C. (2019): SIRT1 inhibits hepatocellular carcinoma metastasis by promoting M1 macrophage polarization via NF-κB pathway. OncoTargets and therapy, 12, 2519.
  17. Chai, R., Fu, H., Zheng, Z., Liu, T., Ji, S., & Li, G. (2017): Resveratrol inhibits proliferation and migration through SIRT1 mediated post translational modification of PI3K/AKT signaling in hepatocellular carcinoma cells. Molecular medicine reports, 16(6), 8037-804
  18. Simone Portmann, Ren_e Fahrner, Antje Lechleiter, Adrian Keogh, Sarah Overney, Alexander Laemmle, Kei Mikami, Matteo Montani, Mario P. Tschan, Daniel Candinas, and Deborah Stroka (2018) Antitumor Effect of SIRT1 Inhibition in Human HCC Tumor Models In Vitro and In Vivo ; Mol Cancer Ther; 12(4) April 2018.
  19. Meseret Derbew Molla , Gashaw Dessie , Yonas Akalu , and Birhanu Ayelign (2020):Hepatocellular Expression of SIRT1 and Its Effect on Hepatocellular Carcinoma Progression: A Future Therapeutic Perspective. International Journal of Hepatology Volume 2020, Article ID 2374615, 10 pages.
  20. Marius Farcas, Andrei-Alexandru Gavrea, Diana Gulei, Calin Ionescu1, Alexandru Irimie, Cristina S. Catana and Ioana Berindan-Neagoe (2019): SIRT1 in the Development and Treatment of Hepatocellular Carcinoma Frontiers in Nutrition September 2019 Volume 6 Article 148.
  21. Bei Zhou, Yun Yang,  Cuiping Li (2019):  SIRT1 inhibits hepatocellular carcinoma metastasis by promoting M1 macrophage polarization via NF-κB pathwayOncoTargets and Therapy 2019:12 2519–2529

Egyptian Journal of Medical Research
Volume 3, Issue 2
April 2022
Pages 170-184

Files

Share

How to cite

Statistics